Advances in Molecular Biomarker for Pulmonary Large Cell Neuroendocrine Carcinoma.
10.3779/j.issn.1009-3419.2020.101.46
- Author:
Jinyao ZHANG
1
;
Lin YANG
2
;
Junling LI
1
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Department of Pathology, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Diagnostic-related marker;
Molecular subtype;
Prognostic-related marker;
Pulmonary large cell neuroendocrine carcinoma
- From:
Chinese Journal of Lung Cancer
2020;23(11):983-988
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a pathological subtype of lung neuroendocrine cancer, which accounts for 2.4%-3.1% in surgical specimens of lung cancer. It is characterized by high invasiveness and poor prognosis, and highly correlated with smoking. There are few relevant studies due to the low incidence and small sample size. Therefore, it is relatively difficult to diagnosis and treatment in clinical practice. In this review, we described molecular subtype, diagnostic and prognostic-related markers about large cell neuroendocrine carcinoma of lung based on the recent progress in genomic sequencing and molecular markers, to find the direction for the next research.
.
